Millions of people living with eczema or psoriasis have been told these are skin conditions — managed with topical creams, steroids, or biologics aimed at the surface of the body. But a growing body of clinical and microbiological research is pointing to a fundamentally different origin: the gut.
The gut-skin-immune axis — a bidirectional communication network linking the intestinal microbiome, systemic immune function, and skin physiology — is reshaping how dermatologists and integrative medicine physicians think about inflammatory skin disease. The inflammation appearing on your skin may, in many cases, be rooted in imbalances happening thirty feet away in your intestinal tract.
The Gut-Skin Axis: More Than a Metaphor
The connection between gut and skin is not new. It was first formally proposed by dermatologists John Stokes and Donald Pillsbury in the 1930s, who observed that patients with acne and skin inflammation often suffered from gut symptoms — and proposed that a microbially disrupted gut contributed to systemic inflammation that ultimately expressed itself on the skin.
Decades later, the tools to test this hypothesis exist. Shotgun metagenomic sequencing, tight junction protein analysis, and cytokine profiling have given researchers the capacity to map the gut-skin-immune relationship with precision. What they've found supports Stokes and Pillsbury's original intuition — and goes considerably further.
The gut microbiome regulates the immune system through several overlapping mechanisms. It trains immune cells in the gut-associated lymphoid tissue (GALT), controls the production of regulatory T cells (Tregs) that suppress inappropriate immune activation, and generates short-chain fatty acids (SCFAs) that reduce systemic inflammation. When the gut microbiome is disrupted — a state called dysbiosis — these regulatory functions break down. The immune system becomes more reactive, inflammatory cytokines increase, and tissues throughout the body — including the skin — bear the consequences.
Eczema (Atopic Dermatitis): A Gut-Dysbiosis Story
Atopic dermatitis, commonly called eczema, is the most prevalent inflammatory skin disease globally, affecting an estimated 10–20% of children and 1–3% of adults. Conventional medicine frames it as a defect in the skin barrier combined with immune hypersensitivity. Both are true. But research increasingly shows that the gut microbiome is a primary driver of both.
Multiple large cohort studies have documented consistent differences in the gut microbiomes of eczema patients compared to healthy controls. Eczema sufferers tend to show reduced microbial diversity, lower populations of Faecalibacterium prausnitzii and Akkermansia muciniphila — both keystone species associated with anti-inflammatory signaling — and elevated populations of Staphylococcus species, both on the skin surface and in the gut.
A landmark 2020 study published in Nature Medicine found that altered gut microbiome composition in infants — specifically low abundance of Lachnospiraceae and other butyrate-producing bacteria — significantly predicted eczema onset in the first year of life, independent of skin barrier genetics. This finding upended the assumption that eczema is primarily a skin-intrinsic condition.
The mechanism involves intestinal permeability — "leaky gut" — which allows bacterial components like lipopolysaccharide (LPS) to enter systemic circulation. LPS activates toll-like receptor 4 (TLR4) on immune cells, triggering a sustained Th2-dominant inflammatory state that drives the IgE hypersensitivity and mast cell activation characteristic of eczema. It's a gut-initiated immune dysregulation that ultimately presents on the skin.
Key Mechanism
Gut dysbiosis → intestinal permeability → systemic LPS translocation → TLR4 immune activation → Th2 skew → elevated IgE and mast cell reactivity → eczema flares. The inflammation starts in the gut, not the skin.
Psoriasis: The Gut Microbiome and Systemic Autoimmunity
Psoriasis is an autoimmune condition characterized by hyperproliferation of keratinocytes — skin cells that replicate far faster than normal, producing the raised, scaly plaques the condition is known for. It is driven by a Th17-dominant immune response: T cells producing interleukin-17 (IL-17) and interleukin-23 (IL-23), which drive epidermal inflammation.
The gut connection to psoriasis is now well established. Multiple studies have found that psoriasis patients harbor significantly different gut microbiomes than healthy controls — with notably reduced populations of Faecalibacterium prausnitzii, Akkermansia muciniphila, and Roseburia intestinalis, all of which produce butyrate and support Treg differentiation. Lower butyrate production means less suppression of Th17 cells — exactly the immune pathway driving psoriatic inflammation.
Research has also found elevated intestinal permeability in psoriasis patients, with increased circulating LPS and inflammatory markers including CRP, TNF-α, and IL-6. A 2019 study in the Journal of Investigative Dermatology demonstrated that psoriasis patients had significantly higher serum zonulin levels — a biomarker of tight junction dysfunction — compared to controls, suggesting that compromised gut barrier integrity is a consistent feature of the disease, not an incidental finding.
Perhaps most striking is the documented relationship between inflammatory bowel disease (IBD) and psoriasis. Patients with Crohn's disease or ulcerative colitis have a three- to four-fold increased risk of developing psoriasis — a figure that points to shared immunological terrain rooted in the gut-immune axis, not coincidence.
The Microbiome, SCFAs, and Skin Immune Regulation
Butyrate deserves particular attention in the context of skin autoimmune conditions. This short-chain fatty acid — produced when gut bacteria ferment dietary fiber — does far more than nourish colonocytes. It functions as a histone deacetylase (HDAC) inhibitor, modulating gene expression across immune cells. In practical terms, butyrate promotes the differentiation of regulatory T cells (Tregs) that act as immune brakes, suppressing the overactive Th2 and Th17 responses driving eczema and psoriasis respectively.
When butyrate-producing bacteria like Faecalibacterium prausnitzii, Roseburia intestinalis, and Clostridium butyricum are depleted — as they commonly are in dysbiotic guts — circulating butyrate levels fall. Treg activity decreases. The immune system loses key restraints on inflammatory signaling, and conditions like eczema and psoriasis are free to escalate.
Propionate and acetate, the other principal SCFAs, also contribute to skin immune homeostasis by influencing mast cell sensitivity and systemic prostaglandin signaling. Together, the SCFAs represent a major pathway through which gut microbial composition directly shapes skin immune reactivity — a pathway that is disrupted in both eczema and psoriasis.
Spore-Based Probiotics and the Gut-Skin Immune Axis
The research on probiotics for eczema and psoriasis is growing, though the field is young. Studies consistently show that probiotic interventions capable of meaningfully colonizing the gut and restoring microbial diversity produce measurable improvements in inflammatory skin conditions — while standard non-spore-forming probiotics, which struggle to survive GI transit, have shown far more inconsistent results.
This is where spore-based probiotics occupy a distinct clinical position. Bacillus subtilis — the core organism in Tundrex formulations, as selected by Dr. Leo Galland from decades of integrative clinical practice — forms resilient endospores that transit the stomach intact and germinate precisely in the small intestine, where immune education occurs. Once active, B. subtilis produces bacteriocins that selectively reduce pathogenic populations while supporting the growth of butyrate-producing commensals.
Critically, Bacillus subtilis has demonstrated the capacity to reinforce intestinal tight junctions — the protein structures that maintain gut barrier integrity. By reducing intestinal permeability, it limits the LPS translocation and systemic immune activation that feed inflammatory skin conditions from the inside out.
A 2021 clinical review in Frontiers in Immunology noted that probiotic strains with documented effects on gut barrier function and Treg induction showed the most consistent benefit in atopic dermatitis — precisely the properties that define the Bacillus subtilis clinical profile. For patients using Tundrex's intensive Tundrex 4 protocol, this is particularly relevant: the higher-dose formula is designed for conditions of significant gut dysbiosis, including those expressing as systemic inflammatory disease.
Clinical Insight
Dr. Leo Galland has observed in his clinical practice that patients with chronic inflammatory skin conditions — including eczema and psoriasis — who present with concurrent gut symptoms (bloating, irregular motility, food sensitivities) often respond to gut-targeted protocols before any skin-directed intervention. In his framework, the skin is frequently the messenger, not the source.
Psoriatic Arthritis: When Gut Dysbiosis Goes Joint-Deep
It's worth noting that approximately 30% of psoriasis patients develop psoriatic arthritis — joint inflammation that can cause significant disability. Research published in Arthritis & Rheumatology found that psoriatic arthritis patients have a distinct gut microbiome signature compared to psoriasis patients without joint involvement, featuring even lower diversity and greater depletion of Akkermansia muciniphila and Coprococcus species.
This suggests a gradient: the more compromised the gut microbiome, the more broadly systemic the inflammatory manifestation becomes — progressing from skin involvement to joint involvement and beyond. Addressing gut dysbiosis early, before systemic autoimmunity deepens, may represent a meaningful window for intervention.
Diet, Polyphenols, and Skin-Protective Gut Ecology
Dietary strategies that support a butyrate-producing, anti-inflammatory gut microbiome can complement probiotic protocols for inflammatory skin conditions. The Mediterranean dietary pattern — rich in diverse plant fibers, polyphenols, and fermented foods — has been associated with lower psoriasis severity in observational studies, likely because of its pronounced prebiotic effect on gut microbial ecology.
Polyphenols from sources like berries, dark leafy greens, green tea, and extra-virgin olive oil feed keystone gut species including Akkermansia muciniphila and Faecalibacterium prausnitzii — the very organisms most depleted in eczema and psoriasis. Omega-3 fatty acids from fatty fish and flaxseed further support Treg activity and reduce Th2/Th17 inflammatory tone.
Conversely, ultra-processed foods, refined sugars, and low-fiber diets consistently impoverish gut microbial diversity and reduce SCFA production — a dietary pattern associated with elevated psoriasis activity in multiple epidemiological studies.
What This Means for Clinical Management
The gut-skin-immune axis is not a fringe concept. It's now a research-supported framework for understanding why inflammatory skin conditions like eczema and psoriasis frequently persist despite optimal topical and systemic treatment — and why some patients experience dramatic improvement when gut health is addressed.
This doesn't mean gut restoration replaces dermatological care. It means the two are not mutually exclusive. Patients who treat the gut alongside the skin — restoring microbial diversity, reinforcing the gut barrier, reducing intestinal permeability, and supporting butyrate production — are addressing the system, not just the symptom.
The Tundrex 1.1 daily maintenance formula provides a foundation for microbiome stability, while the more intensive Tundrex 4 protocol is designed for individuals managing significant gut dysbiosis and its downstream systemic effects — including those who notice that skin inflammation and gut symptoms tend to rise and fall together.
Address the Root, Not Just the Surface
Inflammatory skin conditions often reflect what's happening beneath the surface — in your gut. Explore Tundrex's clinical-grade spore-based protocols, formulated by Dr. Leo Galland to restore the gut microbiome, reinforce the gut barrier, and support systemic immune balance.
Explore Protocols